#Industrial Biotech #Biomanufacturing / Pharmaceutical Services
- Recombinant protein production
- Next-gen bio manufacturing platform
- Synthetic biology
- Metabolic engineering
- Bioproduction
- Bio-sourced molecules
- Bioeconomics / Sustainable development
As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.
Discover >Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.
Discover >Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.
Discover >Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.
Discover >#Industrial Biotech #Biomanufacturing / Pharmaceutical Services
Production as a service (PaaS) platform capable of producing recombinant proteins & enzymes cheaper and on a scale
Proteinea is an insect-based biotechnology startup. Proteinea defines the economics of building with biology by offering a one-step process to produce high-quality recombinant proteins of interest in an affordable, environmentally sustainable, and predictable manner.
Proteinea is integrating biology with engineering and molecular sciences to build the next-gen bio-manufacturing platform. Proteinea has developed a patent-pending technology, called InsectaPro, for using insects as mini-bioreactors to produce recombinant proteins on a scale at a significantly lower cost. It’s robust, scalable, and significantly more advantageous than conventional bioreactors.
Proteinea has a production as a service model (PaaS), in which the company secures partnerships with companies to sustainably produce (biobased and biodegradable) proteins/enzymes of interest in order to significantly reduce their environmental impact and produce at a large-scale and competitive cost coupled with high quality.
Proteinea joined IndieBio, the largest biotech accelerator, in during the winter/spring 2021 cohort.
Collaborations Sought
One of the areas Proteinea is aiming to collaborate is in the vaccine production field.
4 Patents
15 Staff members
Strengths:
Proteinea is offering a one-step process to produce high-quality recombinant proteins of interest in an affordable, environmentally sustainable, and predictable manner.
Innovation Assets:
Using insects as mini-bioreactors to produce recombinant proteins on a scale at a significantly lower cost.
In same field